Expanded FDA Approval Allows Use of Pluvicto Prior to Chemotherapy in Patients with mCRPC
Recent research demonstrated a 59 percent reduced risk of progression or death with the radioligand therapy Pluvicto in comparison to a change of androgen receptor pathway inhibitor (ARPI) for patients with metastatic castration-resistant prostate cancer (mCRPC).
The Food and Drug Administration (FDA) has granted expanded approval of the radioligand therapy 177Lu-PSMA-617 (Pluvicto®, Novartis) for patients with metastatic castration-resistant prostate cancer (mCRPC).
For patients with prostate-specific membrane antigen (PSMA) positive mCRPC, Pluvicto may be utilized for those who have received an androgen receptor pathway inhibitor (ARPI) and prior to the use of chemotherapy, according to Novartis.
For patients with prostate-specific membrane antigen (PSMA) positive mCRPC, the FDA has granted expanded approval of the radioligand therapy Pluvicto for those who have received an androgen receptor pathway inhibitor (ARPI) and prior to the use of chemotherapy. (Image courtesy of Adobe Stock.)
A recently published phase 3 trial revealed that Pluvicto, in comparison to a change of ARPI, reduced the risk of radiographic progression and death by 59 percent in this patient population.
Novartis added that the primary adverse events for patients treated with Pluvicto in the study were dry mouth (61 percent), fatigue (53 percent) and nausea (32 percent).
"This approval is a significant step forward and should open the doorway to a therapy that has clear clinical advantages for the patient with mCRPC who has progressed on one ARPI and has not received chemotherapy,” emphasized Michael Morris, M.D., the principal investigator of the study and prostate cancer section head at the Memorial Sloan Kettering Cancer Center in New York City.
GE HealthCare Launches PET MPI Agent Flyrcado at ACC Conference
March 28th 2025The positron emission tomography myocardial perfusion imaging (PET MPI) agent, which offers a significantly higher half-life than other cardiac PET agents, was recently granted pass-through payment status by CMS that will go into effect on April 1, 2025.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
Study: Monitoring of Prostate MRI Exams Could Lead to 75 Percent Reduction of Gadolinium Contrast
March 17th 2025While DCE MRI was deemed helpful in over 67 percent of cases in which it was used, researchers found that monitored prostate MRI exams, which facilitated a 75 percent reduction of DCE MRI sequences, had comparable sensitivity for prostate cancer as non-monitored exams.
